Department of Anesthesiology, Children's Hospital Colorado & University of Colorado Anschutz Medical Campus, 13123 East 16th Avenue, Box 090, Aurora, CO, 80045, USA.
Department of Clinical Services, Vero Biotech Inc, Atlanta, GA, USA.
J Clin Monit Comput. 2024 Oct;38(5):1155-1162. doi: 10.1007/s10877-024-01143-4. Epub 2024 Jun 1.
Nitric oxide (NO), a selective pulmonary vasodilator, can be delivered via conventional ICU and anesthesia machine ventilators. Anesthesia machines are designed for rebreathing of circulating gases, reducing volatile anesthetic agent quantity used. Current cylinder- and ionizing-based NO delivery technologies use breathing circuit flow to determine NO delivery and do not account for recirculated gases; therefore, they cannot accurately dose NO at FGF below patient minute ventilation (MV). A novel, cassette-based NO delivery system (GENOSYL DS, Vero Biotech Inc.) uses measured NO concentration in the breathing circuit as an input to an advanced feedback control algorithm, providing accurate NO delivery regardless of FGF and recirculation of gases. This study evaluated GENOSYL DS accuracy with different anesthesia machines, ventilation parameters, FGFs, and volatile anesthetics. GENOSYL DS was tested with GE Aisys and Dräger Fabius anesthesia machines to determine NO dose accuracy with FGF < patient MV, and with a Getinge Flow-i anesthesia machine to determine NO dose accuracy when delivering various volatile anesthetic agents. Neonatal and adult mechanical ventilation parameters and circuits were used. GENOSYL® DS maintained accurate NO delivery with all three anesthesia machines, at low FGF with recirculation of gases, and with all volatile anesthetic agents at different concentrations. Measured NO levels remained acceptable at ≤ 1 ppm with set NO dose ≤ 40 ppm. GENOSYL DS, with its advanced feedback control algorithm, is the only NO delivery system capable of accurately dosing NO with anesthesia machines with rebreathing ventilation parameters (FGF < MV) regardless of anesthetic agent.
一氧化氮(NO)是一种选择性肺血管扩张剂,可以通过常规 ICU 和麻醉机呼吸机输送。麻醉机是为循环气体的再呼吸而设计的,减少了挥发性麻醉剂的使用量。目前的基于钢瓶和电离的 NO 输送技术使用呼吸回路流量来确定 NO 输送,并且不考虑再循环气体;因此,它们不能在 FGF 低于患者分钟通气量(MV)的情况下准确地为 NO 定剂量。一种新型的基于盒式的 NO 输送系统(GENOSYL DS,Vero Biotech Inc.)使用呼吸回路中的测量 NO 浓度作为输入,采用先进的反馈控制算法,无论 FGF 和气体再循环如何,都能提供准确的 NO 输送。本研究评估了不同麻醉机、通气参数、FGF 和挥发性麻醉剂对 GENOSYL DS 的准确性。使用 GE Aisys 和 Dräger Fabius 麻醉机测试 GENOSYL DS,以确定 FGF < MV 时的 NO 剂量准确性,并使用 Getinge Flow-i 麻醉机在输送各种挥发性麻醉剂时确定 NO 剂量准确性。使用新生儿和成人机械通气参数和回路。GENOSYL® DS 与所有三种麻醉机一起,在低 FGF 气体再循环时,以及在所有不同浓度的挥发性麻醉剂时,都能保持准确的 NO 输送。在设定的 NO 剂量≤40ppm 时,测量的 NO 水平在≤1ppm 时仍然可以接受。GENOSYL DS 凭借其先进的反馈控制算法,是唯一能够在具有再呼吸通气参数(FGF < MV)的麻醉机上准确地为 NO 定剂量的 NO 输送系统,而与麻醉剂无关。